Kailera Therapeutics

Kailera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing a broad portfolio of next-generation therapies for obesity and metabolic disorders. The company's pipeline is built around several differentiated incretin-based programs designed to offer improved efficacy and convenience for patients. Kailera's lead assets include KLR-102, a long-acting GLP-1/GIP/glucagon receptor tri-agonist currently in clinical development, as well as oral small molecule GLP-1 receptor agonists. These programs aim to address the global obesity epidemic by providing potent weight loss solutions and managing comorbid conditions such as type 2 diabetes and cardiovascular disease. Formed with a significant capital commitment and a suite of licensed assets from Jiangsu Hengrui Pharmaceuticals, Kailera is led by a management team with extensive experience in the biotechnology and metabolic sectors. The company is positioned to compete in the rapidly expanding incretin market by leveraging its diverse clinical-stage portfolio and focusing on the next wave of innovation in metabolic health.